Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Biologic therapy.

Kyorin University Faculty of Medicine, Tokyo, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:5City/State/Province:Tokyo
Treatments:Biologic therapyHospital:Kyorin University Faculty of Medicine
Drugs:Journal:Link
Date:Jul 2012

Description:

Patients:
This phase II study involved 31 patients with recurrent malignant glioma previously treated with temozolomide plus radiotherapy. The median age was 54 years; 51.6% were male.

Treatment:
Patients were treated with the biologic therapy agent bevacizumab, a monoclonal antibody against vascular endothelial growth factor that interferes with cancer cell growth.

Toxicities:
There was one reported death due to brain edema (swelling), which may or may not have been related to treatment. Grade 3-4 congestive heart failure and high blood pressure were also reported.

Results:
The median overall survival was 10.5 months.

Support:
This study was supported by the Chugai Pharmaceutical company.

Correspondence: Dr. Motoo Nagane; email: [email protected]



Back